Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$449.81M$449.81Mderived−0.5% vs Q4 2020 Net Income-$57.90M-$57.90MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$65,880,000N/M Operating Cash Flowderived$11,180,000N/M Free Cash Flowderived-$17,558,000N/M Margins · derivedOperating margin-14.6%−3.3 pt vs Q4 2020
Net margin-12.9%−16.6 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 25, 2022 · 56 d after period end